Axio BioPharma News and Resources

eMBR Genomics and Axio BioPharma have partnered to introduce MKLP1 Pro antibodies, marking their first global commercial release. These antibodies, developed from extensive research into midbody remnants (MBRs), are designed to support advancements in cancer research and diagnostics. MBRs, large

Axio BioPharma has announced that it is now accepting recombinant protein manufacturing projects, marking a step forward in its mission to support the biopharmaceutical industry. Operating from Forward BIOLABS in Madison, Wisconsin, the company specializes in the small-scale production of